Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Biomea Fusion Stock Up 4.6%

Shares of Biomea Fusion stock opened at $1.14 on Monday. Biomea Fusion has a fifty-two week low of $0.87 and a fifty-two week high of $3.08. The business’s fifty day moving average is $1.32 and its two-hundred day moving average is $1.44. The firm has a market cap of $80.60 million, a PE ratio of -0.48 and a beta of -0.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BMEA. Scientech Research LLC purchased a new stake in shares of Biomea Fusion during the third quarter valued at approximately $25,000. Engineers Gate Manager LP purchased a new position in shares of Biomea Fusion in the second quarter valued at $26,000. Millennium Management LLC grew its holdings in Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock valued at $32,000 after purchasing an additional 15,675 shares in the last quarter. Virtu Financial LLC acquired a new stake in Biomea Fusion during the 3rd quarter valued at $39,000. Finally, State Street Corp grew its holdings in Biomea Fusion by 17.8% during the 4th quarter. State Street Corp now owns 165,115 shares of the company’s stock valued at $205,000 after purchasing an additional 25,000 shares in the last quarter. 96.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on BMEA shares. D. Boral Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Biomea Fusion in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. Finally, Rodman & Renshaw assumed coverage on shares of Biomea Fusion in a research note on Tuesday, January 13th. They set a “buy” rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.78.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.